Clinical trials: Prostate-Specific Antigen
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese…
- Trial name
- NCT05670106
- Testing
- [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11
- Where
- 17 sites in China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Glioma, Astrocytoma
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids…
- Conditions
- Glioma, Astrocytoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT06241391
- Testing
- PSMA PET-CT
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Ovarian Carcinoma
68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other…
- Trial name
- NCT03857087
- Testing
- Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance
This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with…
- Trial name
- NCT03579654
- Testing
- Proscavax
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- OncBioMune Pharmaceuticals
Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
The purpose of this study is to see if positron emission tomography/ magnetic resonance imaging (PET/MRI) can be used to monitor the effectiveness of cancer treatment using an investigational radioactive drug called [Ga-68]PSMA.
- Conditions
- Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT02978586
- Testing
- [Ga-68]PSMA PET/MR
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer
Prostate cancer is the most common cancer among men in the United States. Through early detection and improved local therapies a large number of men will be cured.
- Trial name
- NCT01417182
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer (Diagnosis)
Virtual Biopsy of Prostate Cancer Using PSMA PET and AI
Prostate cancer is the most common type of cancer in Norwegian men, but many tumors are slow-growing and do not require treatment.
- Trial name
- NCT07266129
- Where
- Norway
- Volunteers
- 220 people
- Sponsor
- University Hospital of North Norway
Prostate Cancer
Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy
Prostate cancer is currently the second most common cause of cancer death in men in Western countries. Lymphadenectomy is the gold standard procedure for staging pelvic lymph node and is classically indicated in intermediate and…
- Trial name
- LFD (NCT01812902)
- Testing
- Radical Prostatectomy
- Where
- Brazil
- Volunteers
- 260 people
- Sponsor
- University of Sao Paulo
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Advanced Prostate Cancer
European Registry of Next Generation Imaging in Advanced Prostate Cancer
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and…
- Conditions
- Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
- Trial name
- RING (NCT06866782)
- Testing
- Imaging
- Where
- 24 sites in Belgium, France and 6 more
- Volunteers
- 600 people
- Sponsor
- Fundacio Puigvert
Prostatic Neoplasms
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management
- Trial name
- NCT06209853
- Testing
- PSMA PET/CT
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Assiut University
Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma)
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.
- Conditions
- Prostate Cancer (Post Prostatectomy), Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Specific Antigen
- Trial name
- PPSARP (NCT07516886)
- Testing
- Radical Prostatectomy
- Where
- Lithuania
- Volunteers
- 500 people
- Sponsor
- Lithuanian University of Health Sciences
Prostate Cancer
The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Obtain PSMA-PET imaging preoperatively and calculate performance for predicting extra-prostatic extension based on whole-mount pathology (gold standard).
- Trial name
- NCT04936334
- Testing
- 68Ga-PSMA-11 PET Scan
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Clinton Bahler
Cancer of Prostate
Dynamic Focusing Evaluation for Prostate Cancer Treatment
Define the best acoustic parameters for the dynamic focusing HIFU transducer in the treatment of localized Prostate Cancer.
- Trial name
- FOC/DYN (NCT03632980)
- Testing
- "Ablatherm Foc/Dyn" or "Focal One" HIFU treatment
- Where
- France
- Volunteers
- 180 people
- Sponsor
- EDAP TMS S.A.
Urinary Tract Infections
Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
The purpose of this clinical trial is compare the incidence of symptomatic or asymptomatic bacteriuria after transrectal ultrasound guided prostate biopsy using a single dose of fosfomycin 3 g one hour before the biopsy compared…
- Trial name
- BIPROST (NCT01803191)
- Testing
- Fosfomycin 3 g, Ciprofloxacin 500 mg
- Where
- 3 sites in Spain
- Volunteers
- 461 people
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Relapsed Prostate Cancer
Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy
This is an open-label, phase II trial in patients with PSA recurrence after prostatectomy. Patients entering the study will all receive initial 50 Gray (Gy) radiotherapy (25 x 2Gy) to the prostate bed and thereafter be classified…
- Trial name
- PROPER (NCT02699424)
- Testing
- External radiation therapy
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Lund University Hospital
Prostate Cancer
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy
The goal of this clinical research study is to create a registry (research database) of clinical data about patients who receive radiation therapy, with or without hormone therapy, to treat prostate cancer that has come back…
- Trial name
- NCT00850941
- Testing
- Questionnaire
- Where
- 3 sites in United States
- Volunteers
- 146 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent…
- Trial name
- NCT05146973
- Testing
- 177Lu-DOTA-TLX591
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area
RATIONALE: Screening may help doctors find prostate cancer sooner, when it may be easier to treat. PURPOSE: This research study is looking at whether patients who are being screened for prostate cancer have been previously…
- Trial name
- NCT00702104
- Testing
- survey administration
- Where
- United States
- Sponsor
- University of California, San Francisco